Strong growth in new pharmaceutical products offset by stocking and pandemic disruption
- Pharmaceuticals £3.9 billion -12% AER, -8% CER, with growth in new and specialty products (+3% CER) including: Respiratory +24% CER; Immuno-inflammation +26% CER; and Oncology +38% CER partly offsetting decline in Established Products -17% CER. HIV -11% CER impacted by 2020 stocking and tender phasing; HIV two-drug regimen sales +41% CER
- Vaccines £1.2 billion -32% AER, -30% CER (Shingrix -47% CER) reflecting government prioritisation of COVID-19 vaccinations. Continue to expect strong growth from Shingrix in H2
- Consumer Healthcare £2.3 billion -19% AER, -16% CER (-9% excluding divestments/brands under review) reflecting year-on-year “pantry-loading” comparison and weak cold/flu season
On track to create New GSK and standalone Consumer Healthcare company in 2022
- Consumer Healthcare JV commercial integration broadly complete; separation activities advancing
- Pharmaceutical portfolio rationalisation continues with cephalosporin divestment announced
- New GSK Investor Update on 23 June to outline strategy, growth outlooks (2022-2031), capital allocation priorities and timing and approach to separation
